MedWatch

Bavarian and other RSV companies navigating uncharted territory

Despite the pharma industry's massive interest in Respiratory Syncytial Virus (RSV), companies still lack established means of evaluating the outcome of phase III trials in the indication. It puts pressure on front-runners like Bavarian Nordic and Reviral.

Photo: /Ritzau Scanpix/Asger Ladefoged

The respiratory illness RSV is a popular indication among pharma giants like Sanofi and Pfizer as well as smaller biotech firms in the US and Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Latest news

See all jobs